Clinical and genetic risk factors for Fulvestrant treatment in post-menopause ER-positive advanced breast cancer patients

BACKGROUND: Among breast cancer (BC) patients, near 40% are post-menopause, and 70%–80% are hormone receptor (HR)-positive. About 30%–40% BC patients who are diagnosed as invasive carcinoma HR-positive BC would eventually develop metastatic breast cancers. In 2016, FALCON trial proves Fulvestrant as...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jingyu, Li, Jing, Wang, Hui, Wang, Yikai, He, Qiongzhi, Xia, Xuefeng, Hu, Zhe-Yu, Ouyang, Quchang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334389/
https://www.ncbi.nlm.nih.gov/pubmed/30646914
http://dx.doi.org/10.1186/s12967-018-1734-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334389/
https://www.ncbi.nlm.nih.gov/pubmed/30646914
http://dx.doi.org/10.1186/s12967-018-1734-x

Ejemplares similares